NatWest Group plc - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 178 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2015. The put-call ratio across all filers is 1.32 and the average weighting 0.1%.

Quarter-by-quarter ownership
NatWest Group plc ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2015$753,000
-41.2%
4,5400.0%0.02%0.0%
Q1 2015$1,280,000
+216.0%
4,540
+74.7%
0.02%
+466.7%
Q4 2014$405,0002,5990.00%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q4 2015
NameSharesValueWeighting ↓
Samsara BioCapital, LLC 640,688$14,787,0002.73%
DeepCurrents Investment Group LLC 416,800$9,620,0000.33%
DUALITY ADVISERS, LP 105,668$2,439,0000.21%
EULAV Asset Management 335,000$7,732,0000.21%
Virtus ETF Advisers LLC 19,375$447,0000.19%
Hennion & Walsh Asset Management, Inc. 135,214$3,121,0000.19%
PDT Partners, LLC 110,592$2,552,0000.18%
KETTLE HILL CAPITAL MANAGEMENT, LLC 70,256$1,622,0000.16%
ALTRINSIC GLOBAL ADVISORS LLC 168,800$3,896,0000.12%
WOODWARD DIVERSIFIED CAPITAL, LLC 8,939$206,0000.12%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders